How Has the Prenatal Testing And Newborn Screening Market Evolved Historically and What is its Current Size?
The prenatal testing and newborn screening market has seen considerable growth due to a variety of factors.
• There has been significant expansion in the prenatal testing & newborn screening market in the past few years. The market is projected to increase from $6.24 billion in 2024 to $6.99 billion in 2025, with a compound annual growth rate (CAGR) of 12.0%.
Factors such as progress in genetic testing, higher maternal age, increased awareness and education, and health policy and laws, have all contributed to the historical growth.
What Does Future Hold for The Prenatal Testing And Newborn Screening Market By 2029?
The prenatal testing and newborn screening market is expected to maintain its strong growth trajectory in upcoming years.
• The market size for prenatal testing and newborn screening is projected to experience a swift expansion in the coming years, escalating to $11.08 billion in 2029 with a compound annual growth rate (CAGR) of 12.2%.
The reason for this growth in the projected period can be traced back to advancements in genetic counseling, cutting-edge technology, point-of-care testing, telemedicine, and remote monitoring. The forecast period is also anticipated to witness trends such as non-invasive prenatal testing (nipt), preimplantation genetic testing (pgt), virtual medical consultations, testing of maternal blood, and screening for hemoglobinopathies and sickle cell diseases.
What Are The Primary Growth Drivers In The Prenatal Testing And Newborn Screening Market?
The rise of genetic diseases in newborns has significantly fuelled the growth of the prenatal testing and newborn screening market. The World Health Organization identifies genetic diseases such as Thalassemia, Sickle Cell Anemia, Hemophilia, Cystic Fibrosis, Tay Sachs disease, Fragile X Syndrome and Huntington’s disease. Sickle cell anemia, a ubiquitous genetic disease, affects millions globally, particularly those of African, American, Cuban, Central American, Saudi Arabian and Indian descent. For instance, research conducted by the Rady Children's Institute for Genomic Medicine in February 2023 revealed that 41% of infant deaths at Rady Children’s Hospital were linked to single-locus genetic diseases. This significant prevalence of genetic diseases in infants has driven demand for the prenatal testing & newborn screening market.
What Is The Segmentation Of The Global Prenatal Testing And Newborn Screening Market?
The prenatal testing & newborn screening market covered in this report is segmented –
1) By Diagnostic Type: Non-Invasive, Invasive
2) By Technology: Screening Technology, Diagnostic Technology
3) By End user: Hospitals, Diagnostic centers
Subsegments:
1) By Non-Invasive: Blood Tests (Cell-Free DNA Testing), Ultrasound, Maternal Serum Screening
2) By Invasive: Amniocentesis, Chorionic Villus Sampling (CVS), Cordocentesis
Pre-Book The Prenatal Testing And Newborn Screening Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends Are Shaping The Prenatal Testing And Newborn Screening Market?
Key players in the prenatal testing and newborn screening sector are launching groundbreaking initiatives using rWGS (rapid Whole Genome Sequencing) technology. This enables prompt and precise detection of genetic disorders in newborns, facilitating immediate diagnostic and remedial steps for better health outcomes. The rWGS technology is a sophisticated genomic method that can sequence a person's entire genome at a fast pace. It is different from conventional genetic tests that target specific genes or areas; instead, rWGS captures all the DNA present in a person's genome to spot genetic variations related to diseases or disorders. For example, Rady Children's Institute for Genomic Medicine, based in the U.S, rolled out a unique program named BeginNGS in June 2022. The program is designed to detect and diagnose nearly 400 genetic disorders with available treatment options before the symptoms show up. BeginNGS is working to optimize genomic sequencing operations and has plans to widen its testing capacity to cover almost 1,000 disorders. The endgame is to make screening for 3.7 million newborns each year a norm in hospitals throughout the country.
Who Are the Key Players In The Prenatal Testing And Newborn Screening Market?
Major companies operating in the prenatal testing & newborn screening market include:
• PerkinElmer Inc.
• Laboratory Corporation of America Holdings (LabCorp)
• Natera Inc.
• Invitae Corporation
• Centogene AG
• Cradle Genomics Inc.
• Roche Diagnostics International AG
• Quest Diagnostics Incorporated
• Baebies Inc.
• Progenity Inc.
• Ravgen Inc.
• Strand Life Sciences Pvt. Ltd.
• Eurofins Scientific
• Illumina Inc.
• Agilent Technologies Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Bio-Rad Laboratories Inc.
• General Electric Company
• Siemens Healthineers AG
• BGI Group
• QIAGEN N.V.
• Veracyte Inc.
• NIPD Genetics
• Novacyt UK
• Ariosa Diagnostics Inc.
• Verinata Health Inc.
• Counsyl a Myriad Company
• GenPath Diagnostics
• Sonic Healthcare Limited
• Cepheid a Danaher Company
• Guardant Health Inc.
• Genetron Health (Beijing) Co. Ltd.
What Are The Regional Insights Into The Prenatal Testing And Newborn Screening Market?
North America was the largest region in the prenatal testing & newborn screening market in 2023. Western Europe was the second largest region in the prenatal testing and newborn screening market. The regions covered in the prenatal testing & newborn screening market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
